Summary. Previous studies have shown that in patients with primary adult myxoedema (PAM) the rise in blood glucose (BG) and plasma insulin (IgI) after various stimuli is higher and more sustained than in normals, so that in this condition insulin resistance may be hypothesized. In the search for factors involved glucose (BG), insulin (IgI), glueagon (IRG), (assayed with an antiserum which is not specific for pancreatic glueagon) and growth hormone (GH), have been determined in blood during the oral glucose tolerance test, OGTT, (100 g), arginine intravenous infusion, ATT (30 g/30 min), and insulin-induced hypoglycemia, ITT (0.1 kg), in patients with PA?r without clinical diabetes, and in normal control subjects. During OGTT, glucose and IRI levels were higher than normal ; on the other hand, IgG (probably gut glucagon, or enteroglueagon) levels were lower than in normals. During ATT blood glucose in PAM was slightly higher than normal at 30' and lower at 90 ~ and 120'; insulin levels were higher than normal at any time; GH and IRG (very likely pancreatic ghe~gon, or nesidioglueagon) responses were lower than normal. During ITT, blood glucose levels dropped slowly but progressively and Gtt levels were lower than normal. It is concluded that in primary adult myxoedema glueagon, both enteric and pancreatic, and growth hormone secretions are impaired. The resistance to insulin action observed in PAM does not seem to be due to an excess of growth hormone or (nesidioglucagon).
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In previous studies [1, 12, 2, 8, 16] an increased frequency of diabetes in primary adult myxoedema (PAN) has been observed, while the frequency of non iatrogenie myxoedema has been shown to be increased in large groups of diabetics [22, 12] .
Insulin assays in the fasting state have demonstrated normal or supernormal levels in patients with primary adult myxoedema [10, 6, 14, 3, 4, 23, 25] ; after various stimuli in these patients a rise to relatively high levels [16, 23, 20] and a slow return to basal values [3] have been observed; somewhat different findings were registered by others [26] . In our studies the behaviour of blood glucose and insulin levels indicated some degree of insulin resistance in primary myxoedema [3] . On the other hand, in patients with iatrogenic hypothyroidism insulin levels have been found lower than in normal subjects [7] and PAM patients [8] . Conflicting data have been obtained in experimental hypothyroidism [24, 17] . In order to clarify these findings and particularly to obtain a better understanding of carbohydrate metabolism in this condition we have undertaken a parallel study of insulin, glucagon and growth hormone levels in blood after provocative tests. To our knowledge few data have been reported by other authors on growth hormone [15, 5, 27] secretion and no data on glueagon levels in blood.
Methods
The study was conducted in a group of subjects with primary adult myxoedema (see Table 1 ) and a normal control group.
The diagnosis of primary adult myxoedema was established on the basis of clinical examination, PBI (less than 3 ~g/100 ml) BMI~ (less than --20~ I TM thyroid uptake (absent or below 10%), antithyroglobulin antibodies (over 1 : 2500, in all eases according to Boyden's method) (s. Table 1 ). None of the individuals studied was grossly overweight.
Patients with clinical diabetes were excluded. All subjects received a diet with 300 g of carbohydrate for at least three days before each test, The following tests were performed after an overnight fast.
1. Standard oral glucose tolerance test, OGTT (100 g per os); performed in 7 PAM subjects and in 8 normal subjects. Blood samples were taken in the fasting state and 30', 60' and 120' after glucose administration.
2. Arginine test, ATT (30 g arginine hydrochloride diluted in 400 ml of water were infused at a constant rate for 30 rain in the eubital vein): performed in 6 PAM subjects and in 7 normal subjects. Blood was taken from the eontralateral cubital vein 30' and 0' before and 20', 30', 45', 60', 90' and 120' after the start of the infusion.
3. Insulin tolerance test, ITT (insulin, 0.1 units/kg b. w. was injected intravenously in 1 rain): carried out in 6 PAM subjects and in 6 normal subjects. Blood was taken from the eontralateral vein at 30' and 0 rain before, and 20', 30', 45', 60', 90', 120' after the injection.
Blood glucose was assayed by the Hoffman method [13] as applied to the Auto-Analyzer; plasma insulin (IRI) by the Hales and I~andle radioimmuno-assay [11] , plasma glueagon i (IRG) by Lawrence's method [18] , growth hormone (GH) by the method of Molinatti and others [21] .
Results

Oral Glucose Tolerance Test (OGTT) Table 2
Blood glucose in the myxoedema group (PAM) is significantly higher than in normal subjects at 60' and 120'.
Analysis of individual curves shows that 4 out of 7 subjects with PAM are clearly diabetic according to the criteria of Fajans and Corm [9] .
Insulin Tolerance Test (ITT) Table 4
The administration of insulin to patients with PAM is followed by a fall in blood glucose which is considerably slower, but more persistent, than in normal subjects; significant differences are observed from 20' to 120'; GH response in PAM is markedly reduced. Statistically significant differences are observed from 20' to 90'.
Comment
The high frequency of abnormal glucose tolerance tests in PAM is in agreement with previous findings obtained by us and by others [1, 2, 8, 16] . In PAM, plasma insulin levels in the fasting state do not differ significantly from normal. After glucose administration they rise progressively above normal levels reaching a maximum of 217 • 69 tzU/ml at 120'; the differences are significant at 120'.
Plasma glucagon in PAM does not differ from normal in the fasting state and soon after glucose administration, but it is lower than normal at 60' and 120' with a significant difference at 60' min.
Arginine Test (ATT) Table 3
In patients with PAM blood glucose increases slightly more than in normal subjects during the arginine infusion, with a significant difference at 30', and subsequently falls to levels significantly lower than normal at 90' and 120'.
Insulin levels are considerably higher than normal throughout the period of observation; the differences are significant at all points from 20' to 90'.
Plasma glucagon response to arginine in PAM patients is smaller than in normal subjects. The difference is statistically significant at 30'.
Growth hormone response in myxoedema is smaller than normal. The difference is significant at 60'.
1 Glucagon antiserum K52 was kindly provided by Dr. I-Ieding of Novo l~esearch Institute, Copenhagen, and we wish here to aknowledge the courtesy.
Earlier reports summarized by Elrick et al. [7] gave contradictory data on glucose tolerance in hypothyroidism. No clear explanation of these discrepancies is apparent; however most of these reports do not concern primary hypothyroidism or do not distinguish primary adult myxoedema from congenital or iatrogenic hypothyroidism, and therefore are not strictly comparable with our data.
The persistence of high insulin levels at 120' after oral glucose in conjunction with elevated blood glucose levels might be the expression of insulin resistance [3] and/or delayed glucose absorption [14] .
The reduced glucagon response to orM glucose in myxoedema is of interest.
Since it is well known that oral administration of glucose is followed by an increase in blood of a material originating from the gut, reacting like glucagon in the immunoassay (enterogtucagon), and K52 antiserum is not specific for pancreatic glucagon, it is likely that material assayed in this test is enteroglucagon. It is possible that the delayed gastric emptying rate, characteristic of myxoedema, may be responsible for a reduced stimnlus to the enteric cells producing gut glucagon. For a definite clarification of the question it would be necessary to use in the immunoassay an antibody capable of distinguishing pancreatic from gut glueagon. 
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The increase in insulin levels following arginine infusion in PAM is strikingly greater than normal. This confirms that PAM subjects are capable of secreting large amounts of insulin. This response to arginine of PAN subjects differs from that which follows either oral or intravenous [3, 8] glucose in that is very prompt. A similar behaviour has been observed by us in PAM after glueagon administration [3] . The different response of beta cells to glucose and respectively to argininc and glucagon may be explained by the existence of different pathways for glucose-induced and arginine-, or glueagon-indueed secretion.
In myxoedema, either glucose metabolism itself or the transmission of the information from the merebrane glucose receptor of the beta cell might be slower than normal, causing a selective impairment of the response to glucose.
The increased blood glucose response observed in PAN patients at the end of the arginine infusion is difficult to explain, while the marked fall observed in these subjects at 90' and 120' is probably a consequence of the very large output of insulin, overcoming insulin resistance.
Plasma glueagon increase in PAM was significantly smaller than in normal subjects; as the increase of IRG levels after arginine is thought to be due to secretion of pancreatic glucagon (nesidioglueagon) [19] our findings should indicate a reduced alpha cell response to arginine in PAM. As hyperglyeacmia and hyperinsulinaemia are known to suppress glueagon secretion, it might be that this mechanism operates in PAM patients during the first phase of the test. On the other hand a reduced glucagon response might contribute to the lower blood glucose levels observed at the end of the test.
In PAM the fall of blood glucose after insulin administration is delayed and the GK response, in agreement with the data published by others [15, 27] , is reduced. The fact that GH response to arginine is also significantly lowered suggests that reduction of the hypoglycaemie response to insulin is not the factor causing the impaired GH secretion in the insulin tolerance test. The poor GH secretion in myxoedema is probably due to an impairment in the reactivity of the hypothalamo-hypophysial axis, possibly connected with a metabolic derangement of the hypothalamie eentres and/or of the pituitary cells.
The behaviour of GH and glueagon does not seem to explain the reduced glucose utilization observed in previous studies. Therefore another explanation must be found. It very likely that in PAN there is a metabolic disturbance which prevents insulin either from reaching reactive sites or from stimulating glucose utilization. 
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